All Stories

  1. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis
  2. Fingolimod does not enhance cerebellar remyelination in the cuprizone model
  3. Cerebrospinal fluid proteomics in multiple sclerosis
  4. The Norwegian Multiple Sclerosis Registry and Biobank
  5. Time trends in the incidence and prevalence of multiple sclerosis in N orway during eight decades
  6. The EnvIMS Study: Design and Methodology of an International Case-Control Study of Environmental Risk Factors in Multiple Sclerosis
  7. Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model
  8. Reduced duration of breastfeeding is associated with a higher risk of multiple sclerosis in both Italian and Norwegian adult males: the EnvIMS study
  9. Vitamin D and IFN-beta in RRMS
  10. Multiple Sclerosis
  11. Neuromyelitis Optica
  12. Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general
  13. Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort
  14. Employment among Patients with Multiple Sclerosis-A Population Study
  15. In-depth Characterization of the Cerebrospinal Fluid (CSF) Proteome Displayed Through the CSF Proteome Resource (CSF-PR)
  16. Vitamin A, D and E and inflammation in RRMS
  17. Effect of high-dose 1.25 dihydroxyvitamin D3on remyelination in the cuprizone model
  18. Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments
  19. Effects of Blood Contamination and the Rostro-Caudal Gradient on the Human Cerebrospinal Fluid Proteome
  20. Deficient Phosphorylation of Stat1 in Leukocytes Identifies Neutralizing Antibodies in Multiple Sclerosis Patients Treated with Interferon-Beta
  21. Month of birth and risk of multiple sclerosis: confounding and adjustments
  22. Re: Vitamin D – hvor mye er nok, og er mer bedre for helsen?
  23. Re: Uetisk av nevrologene ikke å tilby pasienter med multippel sklerose cytostatikabehandling med autolog stamcellestøtte
  24. Deep Gray Matter Demyelination Detected by Magnetization Transfer Ratio in the Cuprizone Model
  25. Inflammation Markers in Multiple Sclerosis: CXCL16 Reflects and May Also Predict Disease Activity
  26. Association of Genetic Markers with CSF Oligoclonal Bands in Multiple Sclerosis Patients
  27. Oligoclonal Band Status in Scandinavian Multiple Sclerosis Patients Is Associated with Specific Genetic Risk Alleles
  28. No evidence of association between mutant alleles of theCYP27B1gene and multiple sclerosis
  29. Alpha-tocopherol and MRI Outcomes in Multiple Sclerosis – Association and Prediction
  30. Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway
  31. Neuromyelitis optica
  32. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM
  33. The Norwegian Multiple Sclerosis Registry and Biobank
  34. Polyunsaturated fatty acids in multiple sclerosis therapy
  35. Poor Sleep in Patients with Multiple Sclerosis
  36. ω-3 Fatty Acid Treatment in Multiple Sclerosis (OFAMS Study)
  37. Polymorphisms of the BDNF gene show neither association with multiple sclerosis susceptibility nor clinical course
  38. The cuprizone model: regional heterogeneity of pathology
  39. Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model
  40. Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655
  41. Risk of MS is not associated with exposure to crude oil, but increases with low level of education
  42. The Risk of Multiple Sclerosis Among Petroleum Workers Exposed to Crude Oil and Other Hydrocarbons
  43. Prevalence and incidence of multiple sclerosis in Oppland County - a cross-sectional population-based study in a landlocked county of Eastern Norway
  44. Association to the Glypican-5 gene in multiple sclerosis
  45. Vitamin D–Dependent Rickets, HLA-DRB1, and the Risk of Multiple Sclerosis
  46. A Multivariate Approach To Reveal Biomarker Signatures for Disease Classification: Application to Mass Spectral Profiles of Cerebrospinal Fluid from Patients with Multiple Sclerosis
  47. Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report
  48. K.-M. Myhr svarer:
  49. Medikamentell behandling av multippel sklerose
  50. Coping with multiple sclerosis: a 5-year follow-up study
  51. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis
  52. Vitamin D treatment in multiple sclerosis
  53. Upregulation of Immunoglobulin-related Genes in Cortical Sections from Multiple Sclerosis Patients
  54. Corticosteroids in the treatment of multiple sclerosis
  55. Antibodies against interferon-beta in multiple sclerosis
  56. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
  57. Discriminating Variable Test and Selectivity Ratio Plot: Quantitative Tools for Interpretation and Variable (Biomarker) Selection in Complex Spectral or Chromatographic Profiles
  58. A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination
  59. Biomarker discovery in mass spectral profiles by means of selectivity ratio plot
  60. Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination
  61. The SH2D2A gene and susceptibility to multiple sclerosis
  62. Vitamin D–Dependent Rickets as a Possible Risk Factor for Multiple Sclerosis
  63. Diagnosis and treatment of multiple sclerosis
  64. mtDNA nt13708A Variant Increases the Risk of Multiple Sclerosis
  65. Pretreatment of Mass Spectral Profiles:  Application to Proteomic Data
  66. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome
  67. High Incidence of Infarction in the Left Cerebral Hemisphere Among Young Adults
  68. Benign multiple sclerosis
  69. Balance and gait improved in patients with MS after physiotherapy based on the Bobath concept
  70. Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients
  71. Ethnic variation of Fcgamma receptor polymorphism in Sami and Norwegian populations
  72. Fcγ receptor IIIA polymorphism as a risk-factor for coronary artery disease
  73. Severity of Guillain–Barré syndrome is associated with Fcγ Receptor III polymorphisms
  74. Fatigue at Long-Term Follow-Up in Young Adults with Cerebral Infarction
  75. Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs
  76. Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients
  77. Interferon-beta Treatment in Multiple Sclerosis; Patients' Experience in the First 100 Patients
  78. Interleukin-10 promoter polymorphisms in patients with multiple sclerosis
  79. TNF-α and -β Gene Polymorphisms in Multiple Sclerosis: A Highly Significant Role for Determinants in the First Intron of the TNF-β Gene
  80. Fcgamma receptor polymorphisms in populations in Ethiopia and Norway
  81. Performance of the SF-36, SF-12, and RAND-36 Summary Scales in a Multiple Sclerosis Population
  82. IgG Fc-receptor polymorphisms in Guillain-Barre syndrome
  83. The Cost of Multiple Sclerosis in Norway - (and How Certain Can We Be?)